Clearside Biomedical to Present at the Ophthalmology Futures European 2021 Virtual Retina Forum
August 23 2021 - 4:05PM
Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical
company dedicated to developing and delivering treatments that
restore and preserve vision for people with serious back of the eye
diseases, announced today that Thomas A. Ciulla, M.D., MBA, Chief
Medical Officer and Chief Development Officer, will present a
company overview at the Ophthalmology Futures European 2021 Virtual
Retina Forum on September 8, 2021. Access to the event is available
here.
A link to the archived webcast may be accessed
on the Clearside website under the Investors section: Events and
Presentations. An archive of the webcast will be available for
three months.
About Clearside Biomedical
Clearside Biomedical, Inc. is a
biopharmaceutical company dedicated to developing and delivering
treatments that restore and preserve vision for people with serious
back of the eye diseases. Clearside’s proprietary SCS
Microinjector® targets the suprachoroidal space (SCS®) and offers
unique access to the macula, retina and choroid where
sight-threatening disease often occurs. The Company’s SCS injection
platform is an inherently flexible, in-office, non-surgical
procedure, intended to provide targeted delivery to the site of
disease and to work with both established and new formulations of
medications. For more information, please visit
www.clearsidebio.com.
Investor and Media Contacts:Jenny Kobin Remy
Bernarda ir@clearsidebio.com(678) 430-8206
Source: Clearside Biomedical, Inc.
Clearside Biomedical (NASDAQ:CLSD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Clearside Biomedical (NASDAQ:CLSD)
Historical Stock Chart
From Apr 2023 to Apr 2024